Cerevel Therapeutics Holdings, Inc. CERE
We take great care to ensure that the data presented and summarized in this overview for Cerevel Therapeutics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CERE
View all-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Fil LTD Hamilton, D03.25MShares$00.14% of portfolio
-
State Street Corp Boston, MA3.11MShares$00.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.35MShares$04.62% of portfolio
-
Norges Bank Oslo, Q82.34MShares$00.01% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.33MShares$03.86% of portfolio
Latest Institutional Activity in CERE
Top Purchases
Top Sells
About CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at CERE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 01
2024
|
Pfizer Inc |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
27,349,211
-100.0%
|
$1,230,714,495
$45.0 P/Share
|
Aug 01
2024
|
Christopher R Gordon |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
65,679,781
-100.0%
|
-
|
Aug 01
2024
|
Christopher R Gordon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,743
-61.94%
|
-
|
Aug 01
2024
|
Bain Capital Investors LLC |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
65,679,781
-100.0%
|
-
|
Aug 01
2024
|
Adam Koppel |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
65,679,781
-100.0%
|
-
|
Aug 01
2024
|
Adam Koppel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,743
-61.94%
|
-
|
Aug 01
2024
|
Ronald C Renaud Jr President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
83,857
-100.0%
|
-
|
Aug 01
2024
|
Ronald C Renaud Jr President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
160,452
-100.0%
|
-
|
Aug 01
2024
|
Douglas E. Giordano |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,743
-61.94%
|
-
|
Aug 01
2024
|
Ramiro Sanchez Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,673
-100.0%
|
-
|
Aug 01
2024
|
Kathleen Tregoning |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,666
-100.0%
|
-
|
Aug 01
2024
|
Kenneth Di Pietro Chief Human Resources Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,042
-100.0%
|
-
|
Aug 01
2024
|
John Renger Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,370
-100.0%
|
-
|
Aug 01
2024
|
Gabrielle Sulzberger |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,876
-91.12%
|
-
|
Aug 01
2024
|
Scott Akamine Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,527
-100.0%
|
-
|
Aug 01
2024
|
Ruth Mckernan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,743
-61.94%
|
-
|
Aug 01
2024
|
Norbert G Riedel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,553
-90.75%
|
-
|
Aug 01
2024
|
Susan Altschuller Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,913
-100.0%
|
-
|
Aug 01
2024
|
Marijn E Dekkers |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
402,326
-100.0%
|
-
|
Aug 01
2024
|
Marijn E Dekkers |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,283
-87.63%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 94K shares |
---|---|
Exercise of conversion of derivative security | 882K shares |
Bona fide gift | 170K shares |
---|---|
Sale (or disposition) back to the issuer | 198M shares |
Open market or private sale | 614K shares |
Disposition due to a tender of shares in a change of control transaction | 27.3M shares |